Skip to main content
Top
Published in: Virology Journal 1/2010

Open Access 01-12-2010 | Research

Characterization of human adenovirus 35 and derivation of complex vectors

Authors: Duncan McVey, Mohammed Zuber, Damodar EttyReddy, Christopher D Reiter, Douglas E Brough, Gary J Nabel, C Richter King, Jason G D Gall

Published in: Virology Journal | Issue 1/2010

Login to get access

Abstract

Background

Replication-deficient recombinant adenoviral vectors based on human serotype 35 (Ad35) are desirable due to the relatively low prevalence of neutralizing antibodies in the human population. The structure of the viral genome and life cycle of Ad35 differs from the better characterized Ad5 and these differences require differences in the strategies for the generation of vectors for gene delivery.

Results

Sequences essential for E1 and E4 function were identified and removed and the effects of the deletions on viral gene transcription were determined. In addition, the non-essential E3 region was deleted from rAd35 vectors and a sequence was found that did not have an effect on viability but reduced viral fitness. The packaging capacity of rAd35 was dependent on pIX and vectors were generated with stable genome sizes of up to 104% of the wild type genome size. These data were used to make an E1-, E3-, E4-deleted rAd35 vector. This rAd35 vector with multiple gene deletions has the advantages of multiple blocks to viral replication (i.e., E1 and E4 deletions) and a transgene packaging capacity of 7.6 Kb, comparable to rAd5 vectors.

Conclusions

The results reported here allow the generation of larger capacity rAd35 vectors and will guide the derivation of adenovirus vectors from other serotypes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Bethune MP, Kostense S, Penders G, Helmus N, Koudstaal W, et al.: Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. Journal of virology 2003, 77: 8263-8271. 10.1128/JVI.77.15.8263-8271.2003PubMedPubMedCentralCrossRef Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Bethune MP, Kostense S, Penders G, Helmus N, Koudstaal W, et al.: Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. Journal of virology 2003, 77: 8263-8271. 10.1128/JVI.77.15.8263-8271.2003PubMedPubMedCentralCrossRef
2.
go back to reference Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, et al.: Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. Journal of virology 2007, 81: 4654-4663. 10.1128/JVI.02696-06PubMedPubMedCentralCrossRef Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, et al.: Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. Journal of virology 2007, 81: 4654-4663. 10.1128/JVI.02696-06PubMedPubMedCentralCrossRef
3.
go back to reference Kostense S, Koudstaal W, Sprangers M, Weverling GJ, Penders G, Helmus N, Vogels R, Bakker M, Berkhout B, Havenga M, Goudsmit J: Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS (London, England) 2004, 18: 1213-1216.CrossRef Kostense S, Koudstaal W, Sprangers M, Weverling GJ, Penders G, Helmus N, Vogels R, Bakker M, Berkhout B, Havenga M, Goudsmit J: Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS (London, England) 2004, 18: 1213-1216.CrossRef
4.
go back to reference Seshidhar Reddy P, Ganesh S, Limbach MP, Brann T, Pinkstaff A, Kaloss M, Kaleko M, Connelly S: Development of adenovirus serotype 35 as a gene transfer vector. Virology 2003, 311: 384-393. 10.1016/S0042-6822(03)00161-2PubMedCrossRef Seshidhar Reddy P, Ganesh S, Limbach MP, Brann T, Pinkstaff A, Kaloss M, Kaleko M, Connelly S: Development of adenovirus serotype 35 as a gene transfer vector. Virology 2003, 311: 384-393. 10.1016/S0042-6822(03)00161-2PubMedCrossRef
5.
go back to reference Flomenberg PR, Chen M, Munk G, Horwitz MS: Molecular epidemiology of adenovirus type 35 infections in immunocompromised hosts. The Journal of infectious diseases 1987, 155: 1127-1134.PubMedCrossRef Flomenberg PR, Chen M, Munk G, Horwitz MS: Molecular epidemiology of adenovirus type 35 infections in immunocompromised hosts. The Journal of infectious diseases 1987, 155: 1127-1134.PubMedCrossRef
6.
go back to reference Gao W, Robbins PD, Gambotto A: Human adenovirus type 35: nucleotide sequence and vector development. Gene therapy 2003, 10: 1941-1949. 10.1038/sj.gt.3302097PubMedCrossRef Gao W, Robbins PD, Gambotto A: Human adenovirus type 35: nucleotide sequence and vector development. Gene therapy 2003, 10: 1941-1949. 10.1038/sj.gt.3302097PubMedCrossRef
7.
go back to reference Sakurai F, Mizuguchi H, Hayakawa T: Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector. Gene therapy 2003, 10: 1041-1048. 10.1038/sj.gt.3301959PubMedCrossRef Sakurai F, Mizuguchi H, Hayakawa T: Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector. Gene therapy 2003, 10: 1041-1048. 10.1038/sj.gt.3301959PubMedCrossRef
8.
go back to reference Berk AJ: Adenoviridae: The Viruses and Their Replication. In Fields Virology. Volume 2. Fifth edition. Edited by: Knipe DM, Howley PM. New York: Lippincott Williams & Wilkins; 2007:2355-2394. Berk AJ: Adenoviridae: The Viruses and Their Replication. In Fields Virology. Volume 2. Fifth edition. Edited by: Knipe DM, Howley PM. New York: Lippincott Williams & Wilkins; 2007:2355-2394.
9.
go back to reference Havenga M, Vogels R, Zuijdgeest D, Radosevic K, Mueller S, Sieuwerts M, Weichold F, Damen I, Kaspers J, Lemckert A, et al.: Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. The Journal of general virology 2006, 87: 2135-2143. 10.1099/vir.0.81956-0PubMedCrossRef Havenga M, Vogels R, Zuijdgeest D, Radosevic K, Mueller S, Sieuwerts M, Weichold F, Damen I, Kaspers J, Lemckert A, et al.: Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. The Journal of general virology 2006, 87: 2135-2143. 10.1099/vir.0.81956-0PubMedCrossRef
10.
go back to reference Babiss LE, Vales LD: Promoter of the adenovirus polypeptide IX gene: similarity to E1B and inactivation by substitution of the simian virus 40 TATA element. Journal of virology 1991, 65: 598-605.PubMedPubMedCentral Babiss LE, Vales LD: Promoter of the adenovirus polypeptide IX gene: similarity to E1B and inactivation by substitution of the simian virus 40 TATA element. Journal of virology 1991, 65: 598-605.PubMedPubMedCentral
11.
go back to reference Lewis JB, Anderson CW: Identification of adenovirus type 2 early region 1B proteins that share the same amino terminus as do the 495R and 155R proteins. Journal of virology 1987, 61: 3879-3888.PubMedPubMedCentral Lewis JB, Anderson CW: Identification of adenovirus type 2 early region 1B proteins that share the same amino terminus as do the 495R and 155R proteins. Journal of virology 1987, 61: 3879-3888.PubMedPubMedCentral
12.
go back to reference Nakai M, Komiya K, Murata M, Kimura T, Kanaoka M, Kanegae Y, Saito I: Expression of pIX gene induced by transgene promoter: possible cause of host immune response in first-generation adenoviral vectors. Human gene therapy 2007, 18: 925-936. 10.1089/hum.2007.085PubMedCrossRef Nakai M, Komiya K, Murata M, Kimura T, Kanaoka M, Kanegae Y, Saito I: Expression of pIX gene induced by transgene promoter: possible cause of host immune response in first-generation adenoviral vectors. Human gene therapy 2007, 18: 925-936. 10.1089/hum.2007.085PubMedCrossRef
13.
go back to reference Bett AJ, Prevec L, Graham FL: Packaging capacity and stability of human adenovirus type 5 vectors. Journal of virology 1993, 67: 5911-5921.PubMedPubMedCentral Bett AJ, Prevec L, Graham FL: Packaging capacity and stability of human adenovirus type 5 vectors. Journal of virology 1993, 67: 5911-5921.PubMedPubMedCentral
14.
go back to reference Basler CF, Horwitz MS: Subgroup B adenovirus type 35 early region 3 mRNAs differ from those of the subgroup C adenoviruses. Virology 1996, 215: 165-177. 10.1006/viro.1996.0019PubMedCrossRef Basler CF, Horwitz MS: Subgroup B adenovirus type 35 early region 3 mRNAs differ from those of the subgroup C adenoviruses. Virology 1996, 215: 165-177. 10.1006/viro.1996.0019PubMedCrossRef
15.
go back to reference Lemiale F, Haddada H, Nabel GJ, Brough DE, King CR, Gall JG: Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41. Vaccine 2007, 25: 2074-2084. 10.1016/j.vaccine.2006.11.025PubMedPubMedCentralCrossRef Lemiale F, Haddada H, Nabel GJ, Brough DE, King CR, Gall JG: Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41. Vaccine 2007, 25: 2074-2084. 10.1016/j.vaccine.2006.11.025PubMedPubMedCentralCrossRef
16.
go back to reference Nan X, Peng B, Hahn TW, Richardson E, Lizonova A, Kovesdi I, Robert-Guroff M: Development of an Ad7 cosmid system and generation of an Ad7deltaE1deltaE3HIV(MN) env/rev recombinant virus. Gene therapy 2003, 10: 326-336. 10.1038/sj.gt.3301903PubMedCrossRef Nan X, Peng B, Hahn TW, Richardson E, Lizonova A, Kovesdi I, Robert-Guroff M: Development of an Ad7 cosmid system and generation of an Ad7deltaE1deltaE3HIV(MN) env/rev recombinant virus. Gene therapy 2003, 10: 326-336. 10.1038/sj.gt.3301903PubMedCrossRef
17.
go back to reference Hamilton MM, Byrnes GA, Gall JG, Brough DE, King CR, Wei LL: Alternate serotype adenovector provides long-term therapeutic gene expression in the eye. Molecular vision 2008, 14: 2535-2546.PubMedPubMedCentral Hamilton MM, Byrnes GA, Gall JG, Brough DE, King CR, Wei LL: Alternate serotype adenovector provides long-term therapeutic gene expression in the eye. Molecular vision 2008, 14: 2535-2546.PubMedPubMedCentral
18.
go back to reference Thomas DL, Schaack J, Vogel H, Javier R: Several E4 region functions influence mammary tumorigenesis by human adenovirus type 9. Journal of virology 2001, 75: 557-568. 10.1128/JVI.75.2.557-568.2001PubMedPubMedCentralCrossRef Thomas DL, Schaack J, Vogel H, Javier R: Several E4 region functions influence mammary tumorigenesis by human adenovirus type 9. Journal of virology 2001, 75: 557-568. 10.1128/JVI.75.2.557-568.2001PubMedPubMedCentralCrossRef
19.
go back to reference Koup RA, Lamoreaux L, Zarkowsky D, Bailer RT, King CR, Gall JG, Brough DE, Graham BS, Roederer M: Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials. Journal of virology 2009, 83: 6318-6322. 10.1128/JVI.00384-09PubMedPubMedCentralCrossRef Koup RA, Lamoreaux L, Zarkowsky D, Bailer RT, King CR, Gall JG, Brough DE, Graham BS, Roederer M: Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials. Journal of virology 2009, 83: 6318-6322. 10.1128/JVI.00384-09PubMedPubMedCentralCrossRef
20.
go back to reference Rafii S, Dias S, Meeus S, Hattori K, Ramachandran R, Feuerback F, Worgall S, Hackett NR, Crystal RG: Infection of endothelium with E1(-)E4(+), but not E1(-)E4(-), adenovirus gene transfer vectors enhances leukocyte adhesion and migration by modulation of ICAM-1, VCAM-1, CD34, and chemokine expression. Circulation research 2001, 88: 903-910. 10.1161/hh0901.089884PubMedCrossRef Rafii S, Dias S, Meeus S, Hattori K, Ramachandran R, Feuerback F, Worgall S, Hackett NR, Crystal RG: Infection of endothelium with E1(-)E4(+), but not E1(-)E4(-), adenovirus gene transfer vectors enhances leukocyte adhesion and migration by modulation of ICAM-1, VCAM-1, CD34, and chemokine expression. Circulation research 2001, 88: 903-910. 10.1161/hh0901.089884PubMedCrossRef
21.
go back to reference Christ M, Louis B, Stoeckel F, Dieterle A, Grave L, Dreyer D, Kintz J, Ali Hadji D, Lusky M, Mehtali M: Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products. Human gene therapy 2000, 11: 415-427. 10.1089/10430340050015888PubMedCrossRef Christ M, Louis B, Stoeckel F, Dieterle A, Grave L, Dreyer D, Kintz J, Ali Hadji D, Lusky M, Mehtali M: Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products. Human gene therapy 2000, 11: 415-427. 10.1089/10430340050015888PubMedCrossRef
22.
go back to reference Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, Truitt DM, Sumida SM, Kishko MG, Arthur JC, et al.: Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 2004, 172: 6290-6297.PubMedCrossRef Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, Truitt DM, Sumida SM, Kishko MG, Arthur JC, et al.: Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 2004, 172: 6290-6297.PubMedCrossRef
23.
go back to reference Lemckert AA, Sumida SM, Holterman L, Vogels R, Truitt DM, Lynch DM, Nanda A, Ewald BA, Gorgone DA, Lifton MA, et al.: Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. Journal of virology 2005, 79: 9694-9701. 10.1128/JVI.79.15.9694-9701.2005PubMedPubMedCentralCrossRef Lemckert AA, Sumida SM, Holterman L, Vogels R, Truitt DM, Lynch DM, Nanda A, Ewald BA, Gorgone DA, Lifton MA, et al.: Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. Journal of virology 2005, 79: 9694-9701. 10.1128/JVI.79.15.9694-9701.2005PubMedPubMedCentralCrossRef
24.
go back to reference Ophorst OJ, Radosevic K, Havenga MJ, Pau MG, Holterman L, Berkhout B, Goudsmit J, Tsuji M: Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infection and immunity 2006, 74: 313-320. 10.1128/IAI.74.1.313-320.2006PubMedPubMedCentralCrossRef Ophorst OJ, Radosevic K, Havenga MJ, Pau MG, Holterman L, Berkhout B, Goudsmit J, Tsuji M: Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infection and immunity 2006, 74: 313-320. 10.1128/IAI.74.1.313-320.2006PubMedPubMedCentralCrossRef
25.
go back to reference Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, Mehtali M: Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. Journal of virology 1996, 70: 4805-4810.PubMedPubMedCentral Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, Mehtali M: Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. Journal of virology 1996, 70: 4805-4810.PubMedPubMedCentral
26.
go back to reference McVey D, Zuber M, Ettyreddy D, Brough DE, Kovesdi I: Rapid construction of adenoviral vectors by lambda phage genetics. Journal of virology 2002, 76: 3670-3677. 10.1128/JVI.76.8.3670-3677.2002PubMedPubMedCentralCrossRef McVey D, Zuber M, Ettyreddy D, Brough DE, Kovesdi I: Rapid construction of adenoviral vectors by lambda phage genetics. Journal of virology 2002, 76: 3670-3677. 10.1128/JVI.76.8.3670-3677.2002PubMedPubMedCentralCrossRef
27.
go back to reference Gall JG, Lizonova A, EttyReddy D, McVey D, Zuber M, Kovesdi I, Aughtman B, King CR, Brough DE: Rescue and production of vaccine and therapeutic adenovirus vectors expressing inhibitory transgenes. Molecular biotechnology 2007, 35: 263-273. 10.1007/BF02686012PubMedCrossRef Gall JG, Lizonova A, EttyReddy D, McVey D, Zuber M, Kovesdi I, Aughtman B, King CR, Brough DE: Rescue and production of vaccine and therapeutic adenovirus vectors expressing inhibitory transgenes. Molecular biotechnology 2007, 35: 263-273. 10.1007/BF02686012PubMedCrossRef
Metadata
Title
Characterization of human adenovirus 35 and derivation of complex vectors
Authors
Duncan McVey
Mohammed Zuber
Damodar EttyReddy
Christopher D Reiter
Douglas E Brough
Gary J Nabel
C Richter King
Jason G D Gall
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2010
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-7-276

Other articles of this Issue 1/2010

Virology Journal 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.